REVIEWState of Radiomics in GlioblastomaTaha, Birra MD; Boley, Daniel PhD; Sun, Ju PhD; Chen, Clark C MD, PhD Author Information Correspondence: Clark C. Chen, MD, PhD, University of Minnesota Neurosurgery, D429 Mayo Memorial Building, 420 Delaware St SE, MMC96, Minneapolis, MN 55455, USA. Email: [email protected] Neurosurgery: August 2021 - Volume 89 - Issue 2 - p 177-184 doi: 10.1093/neuros/nyab124 Buy EDITOR'S CHOICE Metrics Abstract Radiomics is an emerging discipline that aims to make intelligent predictions and derive medical insights based on quantitative features extracted from medical images as a means to improve clinical diagnosis or outcome. Pertaining to glioblastoma, radiomics has provided powerful, noninvasive tools for gaining insights into pathogenesis and therapeutic responses. Radiomic studies have yielded meaningful biological understandings of imaging features that are often taken for granted in clinical medicine, including contrast enhancement on glioblastoma magnetic resonance imaging, the distance of a tumor from the subventricular zone, and the extent of mass effect. They have also laid the groundwork for noninvasive detection of mutations and epigenetic events that influence clinical outcomes such as isocitrate dehydrogenase (IDH) and O6-methylguanine-DNA methyltransferase (MGMT). In this article, we review advances in the field of glioblastoma radiomics as they pertain to prediction of IDH mutation status and MGMT promoter methylation status, as well as the development of novel, higher order radiomic parameters. © Congress of Neurological Surgeons 2021.